IRIS
PEPE, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.534
NA - Nord America 3.643
EU - Europa 3.364
SA - Sud America 574
AF - Africa 84
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.478
SG - Singapore 2.509
RU - Federazione Russa 1.393
CN - Cina 1.093
IT - Italia 1.035
VN - Vietnam 813
HK - Hong Kong 496
BR - Brasile 458
DE - Germania 222
FR - Francia 176
IN - India 140
NL - Olanda 115
KR - Corea 100
GB - Regno Unito 94
JP - Giappone 91
CA - Canada 83
FI - Finlandia 62
BD - Bangladesh 60
ES - Italia 60
AR - Argentina 52
MX - Messico 50
UA - Ucraina 41
IQ - Iraq 39
PH - Filippine 37
PL - Polonia 25
IE - Irlanda 24
SE - Svezia 22
ZA - Sudafrica 21
EC - Ecuador 20
TH - Thailandia 20
ID - Indonesia 19
AT - Austria 15
PK - Pakistan 15
TR - Turchia 15
CI - Costa d'Avorio 13
LT - Lituania 12
TW - Taiwan 12
VE - Venezuela 12
EG - Egitto 10
NP - Nepal 10
UZ - Uzbekistan 10
GR - Grecia 8
RO - Romania 8
TN - Tunisia 8
BE - Belgio 7
CO - Colombia 7
JM - Giamaica 7
JO - Giordania 7
MA - Marocco 7
PY - Paraguay 7
RS - Serbia 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CH - Svizzera 6
CR - Costa Rica 6
PE - Perù 6
DZ - Algeria 5
MY - Malesia 5
UY - Uruguay 5
AL - Albania 4
AU - Australia 4
CL - Cile 4
KE - Kenya 4
KZ - Kazakistan 4
BO - Bolivia 3
BS - Bahamas 3
ET - Etiopia 3
GE - Georgia 3
HR - Croazia 3
IL - Israele 3
NI - Nicaragua 3
PS - Palestinian Territory 3
PT - Portogallo 3
AZ - Azerbaigian 2
BN - Brunei Darussalam 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GA - Gabon 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
KW - Kuwait 2
LY - Libia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
BF - Burkina Faso 1
BW - Botswana 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DM - Dominica 1
EU - Europa 1
Totale 13.187
Salva come PNG Salva come JPEG
Città #
Singapore 1.259
San Jose 717
Hong Kong 483
Hefei 437
Ashburn 344
Moscow 337
Chandler 282
Beijing 249
Ho Chi Minh City 244
Hanoi 178
Naples 163
Santa Clara 127
Lauterbourg 121
Milan 108
Los Angeles 103
The Dalles 101
Seoul 83
Tokyo 81
Munich 80
Kochi 70
Rome 70
New York 64
Buffalo 62
Millbury 62
Lawrence 56
Redondo Beach 54
Dallas 53
São Paulo 53
Des Moines 47
Amsterdam 46
Haiphong 41
Napoli 40
Boston 34
Helsinki 34
Da Nang 31
Valencia 30
Orem 27
Boardman 26
Council Bluffs 26
Frankfurt am Main 26
Mexico City 25
Wilmington 24
Seattle 23
Montreal 21
London 20
Atlanta 19
Baghdad 19
Warsaw 19
Falkenstein 18
Rio de Janeiro 18
Chicago 17
Bologna 16
Guangzhou 16
Houston 16
Nuremberg 16
Toronto 16
Turku 16
Biên Hòa 15
Brooklyn 15
Turin 15
Bari 14
Chennai 14
Denver 14
Nanjing 14
Ottawa 14
Phoenix 14
Stockholm 14
Hải Dương 13
Dublin 12
Fairfield 12
Can Tho 11
Florence 11
Genoa 11
San Francisco 11
Belo Horizonte 10
Johannesburg 10
Shanghai 10
Bangkok 9
Curitiba 9
Memphis 9
Princeton 9
Quito 9
Salt Lake City 9
Tashkent 9
Brasília 8
Buenos Aires 8
Lappeenranta 8
Tianjin 8
Trieste 8
Aversa 7
Bexley 7
Düsseldorf 7
Krefeld 7
Madrid 7
New Delhi 7
Ninh Bình 7
Poplar 7
Redwood City 7
Ribeirão Preto 7
Salvador 7
Totale 7.202
Salva come PNG Salva come JPEG
Nome #
Performance analysis of SiRe next-generation sequencing panel in diagnostic setting: focus on NSCLC routine samples 223
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing 193
Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting. 187
Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients 167
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. 166
Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens 163
Technical Validation of a Fully Integrated NGS Platform in the Real-World Practice of Italian Referral Institutions 162
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience 157
Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study 152
Liquid biopsy as indication of tumour progression in lung cancer: A potential intervention in tertiary prevention 152
Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study 150
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 148
Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions 145
ALK and ROS1 testing on lung cancer cytologic samples: Perspectives 144
RNA-based next generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center 143
RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer 138
Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study 136
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C‐mutated advanced non‐small cell lung cancer 136
Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients 135
Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma 135
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 133
Cytology meets next generation sequencing and liquid biopsy: A case of lung adenocarcinoma presenting as metastasis to the phalanx 133
Liquid biopsy for BRAF mutations testing in non-small cell lung cancer: A retrospective study 133
Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer 130
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 130
Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens 130
Circulating tumor DNA in cancer: Predictive molecular pathology meets mathematics 130
Next generation sequencing in cytology 130
Antitumor efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models. 129
Predictive molecular pathology in the time of COVID-19 129
Methods for actionable gene fusion detection in lung cancer: now and in the future 128
Next Generation Sequencing for liquid biopsy based testing in Non-Small Cell Lung Cancer in 2021 127
The role of liquid biopsy in epithelial ovarian cancer: state of the art 125
EGFR mutation detection by microfluidic technology: a validation study. 125
Harmonization of Next-Generation Sequencing Procedure in Italian Laboratories: A Multi-Institutional Evaluation of the SiRe® Panel 125
The evolving role of liquid biopsy in lung cancer 124
Liquid Biopsy in Prostate Cancer Management{\textemdash}Current Challenges and Future Perspectives 124
KRAS mutations testing in non-small cell lung cancer: The role of Liquid biopsy in the basal setting 123
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR 122
Mismatch repair proteins and microsatellite instability in solid pseudopapillary neoplasm of the pancreas 121
Brca1/2 ngs somatic testing in clinical practice: a short report 121
Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting 119
Next Generation Sequencing in Cytopathology: Focus on Non-Small Cell Lung Cancer 119
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 118
Osimertinib 118
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer 118
Tumor mutational burden on cytological samples: A pilot study 118
BRAF: A Two-Faced Janus 118
BRAF mutations in lung cancer 117
EGFR T790M detection rate in lung adenocarcinomas at baseline using droplet digital PCR and validation by ultra-deep next generation sequencing 117
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 116
Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations 116
Comparison between two different next generation sequencing platforms for clinical relevant gene mutation test in solid tumours 114
Liquid Biopsy Analysis in Clinical Practice: Focus on Lung Cancer 114
EGFR exon 19 deletion switch and development of p.L792Q mutation as a new resistance mechanism to osimertinib: A case report and literature review 113
Prognostic role of postoperative persistence of ctDNA molecular signature after liver resection for colorectal liver metastases: Preliminary results from a prospective study 111
Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment 111
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective 111
Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report 110
Microsatellite instability evaluation of patients with solid tumour: routine practice insight from a large series of Italian referral centre 110
Next generation sequencing identifies novel potential actionable mutations for grade I meningioma treatment 109
An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples 108
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy 107
Evaluation of a novel liquid biopsy-based ColoScape assay for mutational analysis of colorectal neoplasia and triage of FIT+ patients: a pilot study 106
Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature 105
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify® Mutation Profiler 105
TargetPlex FFPE-Direct DNA Library Preparation Kit for SiRe NGS panel: an international performance evaluation study 104
Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls 101
The Impact of potential ‘confounders’ on the diagnostic sensitivity of circulating free DNA in management of FIT+ patients: a pilot study 100
Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcinoma: A Case Report 100
MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice 100
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy 97
Liquid biopsy testing in urological cancers: Focus on urine 94
Harmonization trial on ESR1 testing strategies in ER+/HER2- breast cancer patients: an Italian experience 93
The Interconnection Between UbcH10, p53, and EGFR in Lung Cancer Cells and Their Involvement in Treatment Response 92
Molecular Testing of Thyroid Fine-Needle Aspiration: Local Issues and Solutions. An Interventional Cytopathologist Perspective 92
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 90
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: practical indications from an Italian multidisciplinary group 89
Microsatellite instability evaluation by automated microfluidic electrophoresis: an update 88
Critical aspects of MSI testing in endometrial cancer: a comparison study 84
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 83
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 81
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 81
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers 79
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 78
Genomics and the early diagnosis of lung cancer 78
Smaller, cheaper, faster: where next for liquid biopsies? 77
Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens 77
Homologous Recombination Deficiency in Ovarian Cancer: from the Biological Rationale to Current Diagnostic Approaches 76
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 76
Uterine Tumours Resembling Ovarian Sex-Cord Tumors: A Case Report and Review of the Literature 75
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy 74
Harnessing the potential of genomic characterization of mutational profiles to improve early diagnosis of lung cancer 72
Circulating biomarkers as predictors of response to immune checkpoint inhibitors in NSCLC: are we on the right path? 71
Predictive biomarkers for molecular pathology in lung cancer 70
Reference standards for gene fusion molecular assays on cytological samples: an international validation study 69
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study 68
Nanoscale Prognosis of Colorectal Cancer Metastasis from AFM Image Processing of Histological Sections 67
Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution 67
The development of a narrow target gene panel makes next generation sequencing effective for circulating free DNA analysis 66
Totale 11.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.775
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.775
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 0 0 14
2021/2022438 26 13 11 4 5 11 3 50 17 47 117 134
2022/2023714 80 52 31 44 89 88 2 82 119 48 69 10
2023/2024584 23 97 42 24 37 39 19 63 18 55 99 68
2024/20253.547 164 176 13 34 87 152 355 226 254 463 1.244 379
2025/20267.719 742 818 828 736 1.245 351 784 497 899 476 281 62
Totale 13.428